Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 45 peer-reviewed journal articles Updated
Endocrinology · Differentiated Thyroid Cancer

Navigating Your Diagnosis: Papillary and Follicular Thyroid Cancer

At a Glance

Papillary and follicular thyroid cancers are usually slow-growing with highly favorable survival rates. Because they are often indolent, modern treatment focuses on safe, less aggressive options like active surveillance or removing only half the thyroid to avoid unnecessary side effects.

Hearing the word “cancer” is a heavy experience that often triggers immediate fear and a sense of urgency. However, for most people diagnosed with Differentiated Thyroid Cancer (DTC)—specifically Papillary Thyroid Carcinoma (PTC) and Follicular Thyroid Carcinoma (FTC)—the reality of the disease is often different from other types of cancer. While it is a serious diagnosis that requires expert care, these cancers are typically slow-growing and have an exceptionally high 10-year survival rate, often exceeding 90% to 95% [1][2].

Understanding “Indolent” Behavior

Many thyroid cancers are described as indolent, meaning they grow very slowly and are unlikely to cause symptoms or spread quickly [1]. Because of this, doctors are increasingly viewing thyroid cancer through a lens of risk management rather than “emergency” surgery. In fact, some very small tumors, known as microcarcinomas, may remain stable or even regress over time without any treatment at all.

The Shift Toward De-escalation

In the past, the standard treatment for almost all thyroid cancers was a total thyroidectomy (removal of the entire gland) followed by Radioactive Iodine (RAI). Today, medical guidelines have shifted toward de-escalation—the practice of using less aggressive treatments when they are just as safe and effective.

  • Thyroid Lobectomy: For many low-risk tumors, surgeons may now recommend removing only the half of the thyroid (one “lobe”) containing the cancer. This allows the remaining half to continue producing hormones, potentially avoiding the need for lifelong thyroid hormone replacement medication [3].
  • Active Surveillance: For very small, low-risk papillary cancers, you and your doctor may choose to monitor the tumor with regular ultrasounds rather than performing surgery right away. This approach can maintain a high quality of life while avoiding surgical risks like voice changes or low calcium levels.
  • Selective Radioactive Iodine (RAI): RAI is no longer used for everyone. It is now reserved primarily for patients with a higher risk of recurrence, as it may not provide a significant benefit for those with low-risk disease [4][5].

Validating the “Good Cancer” Paradox

You may hear people call thyroid cancer the “good cancer” because of its high survival rate. While well-intentioned, this phrase can feel dismissive of the very real emotional and physical toll of the diagnosis. Research shows that thyroid cancer survivors often report a lower quality of life than survivors of more aggressive cancers.

Survivors frequently deal with:

  • Psychological Distress: Significant anxiety regarding “fear of recurrence” (the cancer coming back) or “scanxiety.”
  • Physical Side Effects: Persistent fatigue, voice issues, or complications from treatments like RAI.
  • Financial Stress: The long-term costs of monitoring and medication can create a unique burden.

It is important to recognize that your fear is valid, even if the medical prognosis is excellent. Managing the emotional impact of the diagnosis is a critical part of your overall care plan.

Explore Your Guide

This resource is designed to help you understand every step of your journey. Use the links below to learn more about specific topics:

01

The Diagnostic Journey: From Discovery to Results

Learn the steps to diagnosing thyroid nodules and cancer. Understand your ultrasound TI-RADS score, FNA biopsy, and Bethesda system pathology results.

02

Biology and Genetics: Understanding Your Specific Subtype

Learn about the biology and genetics of papillary and follicular thyroid cancer. Understand BRAF and TERT mutations, tumor spread, and the NIFTP diagnosis.

03

Decoding the Pathology Report

Learn how to read your thyroid cancer pathology report. Understand terms like extrathyroidal extension, vascular invasion, margins, and aggressive variants.

04

Staging and Risk: Understanding Your Outlook

Understand how doctors use AJCC staging to predict thyroid cancer survival and ATA risk stratification to predict recurrence, plus how TSH suppression works.

05

Standard of Care: Personalizing Your Treatment Plan

Learn about standard treatments for differentiated thyroid cancer. Understand your options for surgery, radioactive iodine (RAI), and TSH suppression therapy.

06

Building Your Care Team: Choosing the Right Specialists

Learn how to build your thyroid cancer care team. Understand the roles of endocrinologists and why choosing a high-volume thyroid surgeon is critical.

07

The Long View: Monitoring and Life After Diagnosis

Learn about life after thyroid cancer treatment. Understand your monitoring plan, thyroglobulin (Tg) tests, neck ultrasounds, and managing levothyroxine.

Common questions in this guide

Is papillary thyroid cancer fast-growing?
Most papillary and follicular thyroid cancers are indolent, meaning they grow very slowly and are unlikely to cause symptoms quickly. Some very small tumors, known as microcarcinomas, may even remain stable for years without needing immediate treatment.
Do I need my entire thyroid removed if I have thyroid cancer?
Not always. For many low-risk tumors, surgeons now recommend a thyroid lobectomy, which removes only the half of the thyroid containing the cancer. This allows the remaining half to keep producing hormones, which can sometimes prevent the need for lifelong daily medication.
What is active surveillance for thyroid cancer?
Active surveillance involves monitoring very small, low-risk papillary cancers with regular ultrasounds instead of having surgery right away. This safe approach allows you to avoid potential surgical risks like voice changes while closely tracking the tumor.
Will I definitely need radioactive iodine (RAI) treatment?
Radioactive iodine is no longer routinely used for everyone diagnosed with thyroid cancer. It is now primarily reserved for patients who have a higher risk of recurrence, as it often provides no significant benefit for low-risk disease.
Why is thyroid cancer sometimes called the 'good cancer'?
People often call it the "good cancer" because it has an exceptionally high survival rate. However, this phrase can feel dismissive of the very real anxiety, physical side effects, and long-term monitoring required, which take a significant emotional toll on patients.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific pathology, am I a candidate for a thyroid lobectomy (removing half the thyroid) instead of a total thyroidectomy?
  2. 2.What are the risks and benefits of active surveillance for my specific tumor size and location?
  3. 3.Based on my risk factors, do I actually need radioactive iodine therapy, or can we safely omit it?
  4. 4.How often will I need follow-up ultrasounds and blood tests if we choose a less aggressive treatment path?
  5. 5.Can you explain the specific 'variant' of my cancer and whether it behaves more aggressively or more indolently?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (5)
  1. 1

    Cytological and Ultrasound Features of Thyroid Nodules Correlate With Histotypes and Variants of Thyroid Carcinoma.

    Sgrò D, Brancatella A, Greco G, et al.

    The Journal of clinical endocrinology and metabolism 2023; (108(11)):e1186-e1192 doi:10.1210/clinem/dgad313.

    PMID: 37265229
  2. 2

    Clinical characteristics, surgical approaches, and prognosis of follicular and papillary thyroid cancer in children and adolescents: a retrospective cohort study.

    Liu Y, Meng T, Ma S, et al.

    Pediatric surgery international 2025; (41(1)):89 doi:10.1007/s00383-025-05990-3.

    PMID: 40019558
  3. 3

    Neoadjuvant tyrosine kinase inhibitor therapy for locally advanced, well-differentiated thyroid cancer.

    Bock R, Arman S, Ardila Pardo GL, et al.

    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2026; doi:10.1016/j.surge.2026.05.001.

    PMID: 42303504
  4. 4

    Radioiodine therapy in the different stages of differentiated thyroid cancer.

    Valerio L, Maino F, Castagna MG, Pacini F

    Best practice & research. Clinical endocrinology & metabolism 2023; (37(1)):101703 doi:10.1016/j.beem.2022.101703.

    PMID: 36151009
  5. 5

    Strategies for Radioiodine Treatment: What's New.

    Sparano C, Moog S, Hadoux J, et al.

    Cancers 2022; (14(15)) doi:10.3390/cancers14153800.

    PMID: 35954463

This guide provides general information about papillary and follicular thyroid cancer for educational purposes. Always consult your endocrinologist or oncologist to determine the best treatment plan and monitoring schedule for your specific diagnosis.

Get notified when new evidence is published on thyroid gland papillary and follicular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.